Mei Nian Health (002044): Date war investment Ali network to consolidate the leading position of the large health industry to replace the cornerstone of the data upgrade of the medical examination industry

Mei Nian Health (002044): Date war investment Ali network to consolidate the leading position of the large health industry to replace the cornerstone of the data upgrade of the medical examination industry
投资要点阿里网络入股,优化股东结构,为美年健康长期全面提高大数据,互联网,数字信息服务打下基础,进一步夯实健康产业龙头位置:公司公告于公司控股股东及一致行动人以及其他股东于 2019On October 25th, 2010, the total share capital of listed companies separately transferred to Ali Network, Hangzhou Xintou, and Shanghai Qijun was separated from the “Share Transfer Agreement” 5.58%, 5.24% and 5.34%, totaling 604,884,840 shares (accounting for 16 of the company’s total share capital).16%), the transfer price resets 12.01 yuan / share.  The company’s appointment of a strategic investor, Ali Networks, will significantly improve and improve the company’s own equity structure and future companies in big data, information technology and big health industry competitors to maintain continuous competition.  1) Technology and port complement each other, 南京夜网 further consolidating and leading the entity inspection industry.First of all, as a leader in the medical examination industry and an important port of preventive medicine, Meinian Health has unparalleled value for Ali’s health industry.At the same time, big data and informatization have gradually become the most important promotion points and industry evolution and upgrade points in the medical service field. For companies with large health data flows such as Midea Health, Ali hospitalization and subsequent cooperation will definitely provide companies withStrong technical support and development and upgrading potential.  2) Optimize the shareholder structure and further release the actual control of pledge risk.In essence, through this transfer, the actual controller of the company, Mr. Yu Rong (shareholding with parties acting in concert), held a total of 22 shares.88%, there is no change of the actual controller, but at the same time it can effectively reduce the pledge risk of the actual controller and those acting in concert.We have seen that from the beginning to the present, the company actually controlled its concerted action pledge ratio continued to decline until Q3 was 65.72%, through this share transfer, its pledge ratio and potential risks are expected to be further reduced, providing a stable external environment for the company’s long-term development.And through dating new strategic investors, Meinian Health gradually improved the best shareholder structure, enhanced the company’s management capabilities, and provided a new perspective and perspective for the company’s development and evolution.  Profit forecast and investment grade: We expect the company’s sales revenue for 2019-2021 to be 104.04 billion, 135.2.5 billion and 179.8.8 billion, the net profit attributable to the parent company was 10.2.6 billion, 13.9.7 billion and 19.3.5 billion.We are optimistic about the rapid expansion of the company’s medical examination business and its value as the entrance to the large health industry. In the future, we will be able to introduce more medical examination items and excavate the application of medical examination data to fully reflect the value of its leading companies in the large health industry.Therefore, we continue to recommend the company and maintain the “Buy” rating.  Risk reminders: policy risks in the medical service industry; mergers and acquisitions to integrate corporate integration and goodwill risks.